Zosano Pharma (NASDAQ:ZSAN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.
Shares of Zosano Pharma (NASDAQ:ZSAN) opened at $0.52 on Friday. The stock has a market cap of $21.62 and a price-to-earnings ratio of -0.44. Zosano Pharma has a 1 year low of $0.50 and a 1 year high of $3.54.
Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05). analysts predict that Zosano Pharma will post -0.9 EPS for the current year.
An institutional investor recently raised its position in Zosano Pharma stock. Northern Trust Corp grew its holdings in Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 79,234 shares of the biotechnology company’s stock after buying an additional 67,774 shares during the period. Northern Trust Corp owned 0.20% of Zosano Pharma worth $112,000 at the end of the most recent reporting period. 19.41% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Zosano Pharma (ZSAN) Rating Increased to Sell at ValuEngine” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2018/01/02/zosano-pharma-zsan-rating-increased-to-sell-at-valuengine.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.